Neurocrine Biosciences, Inc. (NBIX)

Neurocrine Biosciences' stock price has been influenced by several events over the past six months. Strong Q3 2025 earnings led to a stock price increase and analyst price target raises. A positive Medicare price negotiation outlook caused the stock to rise. A director sold 15,000 shares of the company's stock. A Phase 2 study for a depression drug did not meet the primary endpoint. A strong first-quarter performance in May 2025 led to a stock surge. Stifel reiterated a "Buy" rating, Morgan Stanley maintained an "Overweight" recommendation, and Zacks identified NBIX as a "Strong Buy" stock.

Neurocrine Biosciences is actively gaining insights into prescriber behavior, patient dynamics, and potential seasonality trends for CRENESITY. The company has observed that the pace of new patient starts may fluctuate quarter-to-quarter, but strong persistence and adherence rates support confidence in continued volume growth. In the third quarter of 2025, patient demand for CRENESITY modestly favored the pediatric population over adults and skewed towards female patients. While the company acknowledges potential seasonality, specific details on the nature or impact of these seasonal trends across its entire product portfolio are not extensively detailed.

Neurocrine Biosciences, Inc. is a neuroscience-focused biopharmaceutical company that discovers, develops, and commercializes treatments for neurological, neuroendocrine, and neuropsychiatric disorders. Its major products include INGREZZA for tardive dyskinesia and chorea associated with Huntington's disease, ALKINDI for adrenal insufficiency, Efmody capsules for classic congenital adrenal hyperplasia, Orilissa tablets for endometriosis, Oriahnn capsules to treat uterine fibroids, and CRENESITY to treat congenital adrenal hyperplasia. The company also has several product candidates in clinical development, targeting conditions such as dyskinetic cerebral palsy, schizophrenia, movement disorders, and major depressive disorder.

Neurocrine Biosciences is headquartered in San Diego, California, and operates in the United States and internationally. Its products, such as INGREZZA, are also commercialized in Japan and other Asian markets through licensing agreements.

Neurocrine Biosciences has maintained a positive brand reputation in the past year, as evidenced by its recognition in Forbes lists for 2025, ranking #52 in "Most Trusted Companies in America" (Drugs & Biotechnology) and #194 in "America's Best Companies" (Drugs & Biotechnology). While the Phase 2 study failure for NBI-1070770 in major depressive disorder is a clinical setback, there is no information suggesting it has significantly impacted the company's overall brand reputation.

Neurocrine Biosciences' stock is primarily held by institutional investors, who collectively own approximately 95.64% to 80.86% of the company's stock. Major institutional owners include BlackRock, Inc., Vanguard Group Inc., Dodge & Cox, JPMorgan Chase & Co, State Street Corp, Price T Rowe Associates Inc /md/, and Aqr Capital Management Llc. Bvf Partners L P is the largest individual shareholder. Insiders own approximately 1.09% to 4.30% of the stock. Recent insider selling activity includes sales by CEO Kyle Gano and Director William H. Rastetter.